Weight Loss
Triple-Agonist Weight Loss Drugs: How Retatrutide and Mazdutide Differ From GLP-1s
The newest weight-loss drugs work by hitting more hormone targets than GLP-1 alone, and the results suggest that more targets can mean more weight…
Amylin-Based Weight Loss Drugs Explained: Cagrilintide, Petrelintide, and Amycretin
Amylin is emerging as the next major target in weight-loss medicine, offering a different mechanism than GLP-1 with a key advantage: gentler side effects….
How Much Weight Can You Lose on Retatrutide? Trial Results Explained
Retatrutide has produced some of the largest weight loss of any drug in development, reaching roughly 24% in mid-stage trials and climbing toward 30%…
Retatrutide Side Effects: What the Early Trials Show
Retatrutide’s side effects are mostly the familiar gastrointestinal ones seen across weight-loss drugs, but it has one distinctive addition: a skin-tingling sensation called dysesthesia…
VK2735: Comparing Viking’s Oral and Injectable Options
Viking Therapeutics is developing VK2735 in two forms, a weekly injection and a daily pill, and the practical difference comes down to convenience versus…
MariTide Results: How Much Weight Amgen’s Monthly Shot May Deliver
In its phase 2 trial, MariTide produced up to about 20% average weight loss over a year in people with obesity, and importantly, the…
Amycretin: Oral vs Injectable, and How Much Weight It May Help You Lose
Amycretin is unusual in that it’s being developed as both a daily pill and a weekly injection, and early data suggests the injection produces…
Survodutide for MASH: Treating Fatty Liver Disease and Obesity Together
Survodutide is being studied for a serious liver disease called MASH (metabolic dysfunction-associated steatohepatitis), and its early results are among the most promising in…
How Much Weight Can You Lose on CagriSema? Trial Results Explained
In its main obesity trial, CagriSema produced an average weight loss of about 22.7% over 68 weeks, which is among the highest seen for…
